Health economics and outcomes research (HEOR)
Real-world evidence (RWE)-based treatment publications to meet the growing value-based pricing, market access, and reimbursement requirements.
HEOR publications to guide managed care decisions
Increased focus on value-based pricing means that life sciences companies need to embrace the “volume-to-value” shift in their organizational DNA. The pressure to systematically demonstrate RWE-based value as medical publications is more significant than ever before – critical to ensuring desired pricing, coverage, and reimbursement throughout the product’s lifecycle.
A sound HEOR capability is crucial for publication planning to guide decision-makers on meeting global patient-access demands.
Benefits
Fully customizable and transparent cost-effectiveness model for a pre-launch drug.
A budget impact model to assess the financial consequences of drug adoption from payers’ perspective.
Estimated RWE-based disease prevalence for granular patient segments using an optimization algorithm.
Differentiated modeling studies
- Deep understanding and experience of diverse data sets
- Deep therapeutic area expertise
- A team of experienced modelers, statisticians, and academic writers
- Extensive HEOR/RWE modeling experience
- Proactive engagement with key stakeholders to design easily scalable and adaptable models
- Statistically robust and clinically sound models
- Design solutions that can withstand scrutiny during evidence dissemination
- Continuous efforts towards implementing disruptive modeling approaches
Axtria research hub
White Paper
The Evolution and Future of Integrated Evidence Planning
Webinar
Evidence Generation: Evolution and Future of Integrated Evidence Planning
Report
HEOR Value Demonstration And Evidence Generation Challenges
Customer success stories
Case Study
Automated Email Campaigns Support The Patient Assistance Journey For Enhanced Treatment Outcomes
Case Study
Patient Flow Analysis For A Global Oncology Leader
Case Study